Algernon Pharmaceuticals CEO Christopher Moreau joined Steve Darling from Proactive to share news the company has been granted permission to conduct a Phase 1 clinical study of an intravenous formulation of AP-188 or DMT for the treatment of stroke. The study will be conducted in the Netherlands at the Centre for Human Drug Research in Leiden. The screening for patients is expected to begin in Q4 or this year. The purpose of the study is to identify the safety, tolerability, and pharmacokinetics of DMT when administered as an intravenous.
Algernon Pharmaceuticals gains approval for Phase 1 clinical study of DMT for treatment of stroke
